BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in hepatocellular carcinoma (HCC) cells

Abstract

Background Excessive hepatic glycogen accumulation benefits tumorigenesis and cancer cell survival. We previously reported that BMP4 has the strongest ability to promote glycogenesis among the 14 BMPs in hepatocytes and augmented hepatocellular carcinoma (HCC) cell survival under hypoxia and hypoglycemia conditions by promoting the glycolysis pathway. However, the mechanism underlying BMP4’s effect on glycogenesis in HCC remains elusive. Methods The expression of BMP4 and SLC2A1 were acquired by analyzing the TCGA-LIHC dataset, as well as by immunohistochemical analysis of the 40 pairs of human HCC samples and para-tumor tissues. Gene expressions were detected by qPCR, immunoflurorescence staining, and Western blotting. Overexpression and silencing of BMP4 were accomplished through adenoviruses Ad-B4 and Ad-siB4 infection. Hepatic glycogen was detected by PAS staining. SLC2A1 (GLUT1) function was blocked by the inhibitor BAY-876. ChIP assay was used to determine the binding of SMADs to the promoter region of SLC2A1 in HCC cells. Lastly, the in vivo effect of BMP4-regulated SLC2A1 on HCC tumor growth was assessed in a xenograft model of HCC. Results The elevated expression of BMP4 in HCC tumor tissues was highly correlated with hepatic glycogen accumulation in clinical samples. SLC2A1 was highly expressed in HCC tumor tissue and correlated with clinical stage and prognosis. Exogenous BMP4 augmented glycogen accumulation and upregulated the expression of glycogen synthesis-related genes in Huh7 and HepG2 cells, both of which were effectively blunted by SLC2A1inhibitor BAY-876. In mechanism, BMP4 activated SMAD5 to regulate the promoter of SLC2A1to enhance its expression. The in vivo xenograft experiments revealed that BMP4 promoted glycogen accumulation and tumor growth, which were effectively diminished by BAY-876. Conclusion These results demonstrate that BMP4 upregulates glycogen synthesis through the SMAD/SLC2A1 (GLUT1) signaling axis in HCC cells, which may be exploited as novel therapeutic targets for HCC treatment.

Engrailed-1 (En-1) Inactivation Leads to Scarless Skin Wound Healing Through Extracellular Matrix (Ecm) Remodeling

“…HEK-293 derivatives 293pTP and RAPA cells were previously described (Wei et al 2017). All cells were cultured in high glucose Dulbecco's modi ed Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (LONSA SCIENCE SRL, Uruguay) containing 100 units of penicillin and 100µg of streptomycin in a 5% CO 2 incubator at 37°C (Zhong et al 2023). Unless indicated otherwise, all chemicals were purchased from Sigma-Aldrich (St Louis, MO, USA), Thermo Fisher Scienti c (Waltham, MA, USA), or Solarbio (Beijing, China).…”

Establishment and characterization of a rat model of scalp-cranial composite defect for multilayered tissue engineering

“…The mouse mesenchymal cell line iMAD was previously described 19,20 . All cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products), 100 U/ml penicillin, and 100µg/ml streptomycin at 37°C in 5% CO 2 as described [21][22][23][24][25][26] . Unless indicated otherwise, chemicals were obtained from Thermo Fisher Scienti c (Waltham, MA) or Millipore Sigma (St. Louis, MO).…”

BMPR2 Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension

“…Recently, BMP4 has been recognized to induce hypoxic glycolytic reprogramming in hepatocellular carcinoma cells, through upregulation of PFKFB3, PKM2, and HK (hexokinase) 2. 85 However, a link between HIF2-α -BMP4 expression and glycolytic reprogramming in vascular cells is yet to be confirmed.…”